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ABSTRACT
Glioblastoma (GBM) is a highly aggressive brain cancer with poor prognosis and 
low survival rate. Invasive cancer stem-like cells (CSCs) are responsible for tumor 
recurrence because they escape current treatments. Our main goal was to study the 
proteome of three GBM subpopulations to identify key molecules behind GBM cell 
phenotypes and potential cell markers for migrating cells. We used SuperQuant–an 
enhanced quantitative proteome approach–to increase proteome coverage. We found 
148 proteins differentially regulated in migrating CSCs and 199 proteins differentially 
regulated in differentiated cells. We used Ingenuity Pathway Analysis (IPA) to predict 
upstream regulators, downstream effects and canonical pathways associated with 
regulated proteins. IPA analysis predicted activation of integrin-linked kinase (ILK) 
signaling, actin cytoskeleton signaling, and lysine demethylase 5B (KDM5B) in CSC 
migration. Moreover, our data suggested that microRNA-122 (miR-122) is a potential 
upstream regulator of GBM phenotypes as miR-122 activation was predicted for 
differentiated cells while its inhibition was predicted for migrating CSCs. Finally, we 
validated transferrin (TF) and procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 
(PLOD2) as potential markers for migrating cells.
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 INTRODUCTION
Glioblastoma (GBM), a WHO grade IV glioma, 
is the most aggressive primary brain cancer [1] with a 
median survival rate of only 15 months [2]. Surgical 
resection combined with radiotherapy and chemotherapy 
is the standard treatment for GBM [2]. However, tumor 
recurrence is inevitable because GBM cells can invade 
surrounding tissues thus preventing full removal of tumor 
cells by resection. Moreover, subpopulations of cancer 
stem-like cells (CSCs), which are resistant to radiotherapy 
and chemotherapy, are present in tumor environment 
[3, 4]. CSCs self-renew and recapitulate the original 
tumor upon cerebral implantation in mice [5]. Evidences 
suggest that CSCs have developed a number of molecular 
mechanisms to escape and survive treatments. For 
example, radiation resistance seems to be due to increased 
activity of the DNA damage response machinery in CSCs 
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[3]. Radiotherapy with concomitant temozolomide (TMZ) 
has increased the survival rate by several months [2], 
however, recurrence is still observed after treatment. 
Understanding the regulatory system of CSCs is 
critical to design next-generation drugs to ultimately 
imbalance CSC homeostasis. Regulation of CSCs in 
gliomas involves extrinsic (microenvironment, niche 
factors and host immune system) and intrinsic (genetic, 
epigenetic, and metabolic) factors [6]. For example, CSCs 
maintain an undifferentiated state by aberrant activation of 
common signaling pathways such as Notch, NF-κB, BMP, 
Wnt, and PI3K-AKT signaling [6]. 
A number of biomarkers are available for glioma 
cells, such as mutation of isocitrate dehydrogenase 1 
(mIDH1) [7, 8], methylation of MGMT gene (DNA repair 
enzyme O6-methylguanine-DNA methyltransferase) [9], 
as well as standard stem cell markers including, but not 
restricted to, CD133, Musashi-1, Bmi-1, Sox-2 and Nestin 
[10, 11]. Some CSCs are able to migrate from the tumor 
core, representing a significant challenge for treatment as 
they are left behind after tumor resection [9, 12]. Although 
standard stem cell markers can be used to identify 
migrating CSCs, these markers cannot be used to select 
the migrating phenotype from other CSCs.
Gene expression analysis is a valuable method in 
cancer research. However, gene counts do not necessarily 
correlate with protein abundances in cells due to mRNA 
regulation and protein turnover. During the past decade, 
mass spectrometry (MS)-based proteomics has become 
the leading technology to study biological systems. Our 
group developed the Complementary Finder software. 
This tool uses high-confidence complementary fragment 
ions to derive individual and unique peptide parent 
masses, deconvoluting mixture spectra and increasing 
proteome coverage [13]. More recently, we implemented 
the SuperQuant method to infer quantitative information 
to the output data of Complementary Finder using MS1 
spectrum-based quantitation. On average, SuperQuant 
allows the identification and quantitation of 10% more 
proteins per study enabling a more insightful proteome 
interpretation [14].
Given the poor prognosis of GBM, the identification 
of specific biomarkers and therapeutic targets for this 
disease are of imminent importance to improve the early 
diagnosis and treatment, including the development of 
personalized medicine [15]. In this study, our goals were 
to identify key regulators and cell markers from different 
phenotypes of GBM cells, focusing on the migrating CSC 
phenotype. We used SuperQuant to assess deeper into the 
GBM proteome of CSC spheroids, migrating CSCs and 
differentiated GBM cells. We identified and quantified the 
protein abundances of more than 2,817 proteins, of which 
304 proteins were found differentially regulated. Among 
regulated proteins, we identified potential therapeutic 
targets and cell markers that could serve as subjects for 
further investigation.
RESULTS AND DISCUSSION
Experimental design used to study proteins 
involved in the GBM migration and differentiation
We used the proteomics pipeline represented in 
Figure 1 to compare the proteome of three GBM cell 
phenotypes. Tissue fragments from a grade IV GBM 
patient subjected to brain tumor resection were obtained 
in a study published previously [16]. Tissue fragments 
were dissociated to the single cell level and thereafter 
they formed spheroids in serum free medium. We decided 
to grow the tumor cells as organotypic tumor spheroids 
(OTS) because 3D culture preserves important features of 
the original tumor tissue, including cell-to-cell interactions, 
thus representing a more in vivo-like model [17, 18]. 
Migrating and differentiated cells were obtained from CSC 
spheroids. To select CSCs with migrating phenotype, we 
used the migration assay reported by Munthe et al. [19] and 
represented in the supporting information (Supplementary 
Figure 1). The migration assay was conducted with stem 
cell medium to maintain cells undifferentiated. On the 
other hand, to produce the differentiated cells we cultured 
the CSC spheroids with medium containing 10% (w/v) 
fetal calf serum (FCS) (Figure 1).
In vitro experiments performed with neural stem 
cells showed that these cells expand and form neurospheres 
when grown under serum-free conditions [20]. Lee et 
al. showed that GBM cells cultured under serum-free 
conditions more closely resembled primary GBMs and 
preserved CSC features [21]. Therefore serum-free medium 
more accurately reflect the cell environment in brain tissue 
compared to serum-containing medium for culturing CSCs.
Recently we reported a new post-acquisition method 
(named SuperQuant) that allows increased quantitative 
proteome depth by extracting co-isolated/co-fragmented 
peptides from MS/MS output files that are neglected in 
a normal shotgun proteomic analysis [14]. SuperQuant 
processing led to the identification and quantitation of 2,817 
protein groups, representing an increment of 7% compared 
to unprocessed data (Supplementary Figure 2, supporting 
information). This improvement is comparable with our 
previous study reporting approximately 10% increase 
of quantified proteins using HeLa cells [14]. To evaluate 
quantitation reproducibility of our method, we calculated 
the coefficient of variance (CV) between replicates for 
each protein. The CVs distributions are presented in 
Supplementary Figure 3 (supporting information). The 
average CV between replicate experiments was 3.5%.
The proteome of CSC spheroids and migrating 
CSCs are more similar than the proteome from 
differentiated cells
Since migrating CSCs and differentiated cells were 
generated from CSC spheroids, we used the dataset of 
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CSC spheroids as reference (denominator) to obtain 
protein ratios. As consequence, upregulation of a given 
protein from the migrating CSCs dataset means that this 
protein is statistically more abundant in migrating CSCs 
than in CSC spheroids. Likewise, down-regulation of a 
given protein from differentiated cells means that this 
protein is differentially more abundant in CSC spheroids 
than in differentiated cells.
Out of 2,817 proteins detected and quantified in 
this study, 199 and 148 were differentially regulated 
in the differentiated and migrating CSCs datasets, 
respectively (Supplementary Table 1). Comparing the 
regulated proteins from both datasets, we observed that 
only 43 proteins (14%) were identified in both datasets 
(Supplementary Figure 4), indicating that the differential 
proteomes from migrating CSCs and differentiated cells 
are rather different.
Hierarchical clustering analysis shows that the 
proteome of CSC spheroids and migrating CSCs are more 
similar than the proteome of differentiated cells (Figure 2). 
Although the similarity is only marginal in relation to the 
proteome of the differentiated cells, this result is likely to 
reflect the stem-like phenotype of spheroids and migrating 
cells [19]. However, we would like to point out that 
even these CSCs have clusters containing proteins with 
opposing abundance profiles indicating genes with distinct 
regulations.
Pathway analysis of migrating CSCs and 
differentiated cells 
Activation z-score in IPA was used to predict 
modulation patterns of the top-scoring canonical pathways. 
This algorithm uses the causal network to predict activation 
Figure 1: Experimental setup. Glioblastoma stem cell-like spheroids were cultured using the serum-free medium to maintain the stem-
like phenotype. Migrating cancer stem-like cells (CSCs) were selected from CSC spheroids using the migration assay reported previously 
and represented in Supplementary Figure 1. Differentiated cells were obtained by culturing CSC spheroids in medium containing 10% 
(w/v) fetal calf serum. After cell lysis and on-filter protein digestion, peptides were labeled with dimethyl labeling. SuperQuant was used 
to increase quantitative proteome coverage.
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or inhibition of given pathways based on experimental data 
and expected expression levels of signaling effectors from 
a curated biological database (Ingenuity Knowledge Base) 
[22].
As shown in Figure 3, IPA predicted opposing 
modulations for all top-scoring canonical pathways from 
migrating CSCs and differentiated cells, except for the 
integrin-linked kinase (ILK) signaling, predicted to be 
activated in both datasets. ILK connects integrin receptors 
with the actin cytoskeleton to regulate many cellular 
processes including proliferation, angiogenesis, survival, 
differentiation, migration, and invasion [23]. The highest 
activation z-score was calculated for migrating cells 
suggesting that ILK signaling is more active in migrating 
CSCs. Data suggest that activation of ILK signaling is 
important for migration of CSCs and differentiation. Since 
GBM recurrence after treatment is thought to be due to 
CSCs [6], our data suggest that inhibition of ILK signaling 
can be a potential treatment for GBM. In fact, a recent 
study has shown that p53-wildtype GBM cells were more 
susceptible to radiotherapy after the knockdown of ILK 
and its signaling partners PINCH1 and ILKAP [24].
Activation of actin cytoskeleton signaling was 
predicted only for migrating CSCs (Figure 3). Actin 
cytoskeleton reorganization is a key process in migration of 
GBM cells. Migrating cells produce actin-rich protrusions 
of the plasma membrane, named invadopodia, which 
interact with the extracellular matrix (ECM) inducing its 
proteolysis and remodeling. The presence of invadopodia 
is usually associated with poor prognosis [25, 26].
As shown in Figure 3, IPA predicted inhibition of 
RhoGDI, PI3K/AKT, RhoA, insulin receptor, CDK5, Rho 
family GTPases, and protein kinase A (PKA) signaling 
pathways for differentiated cells. This data suggest that 
the inhibition of these signaling pathways is important for 
GBM differentiation. Regarding PI3K/AKT signaling, its 
activation is a key mechanism in glioma progression to 
higher-grade tumors. Increased activity of PI3K/AKT in 
CSCs induces resistance by enhancing expelling of drugs 
via ABC transporters [27]. Moreover, CSC is maintained 
undifferentiated by aberrant activation of PI3K/AKT [6].
Prediction of upstream regulators for migrating 
CSC and differentiated cell proteomes
Figure 4A shows the predicted upstream regulators. 
For the differentiated cells, IPA predicted activation of 
microRNA 122 (miR-122) (z-score = 2.998) and tumor 
antigen p53 (Tp53) (z-score = 2.425), and inhibition of 
tumor antigen p63 (Tp63) (z-score = -0.083). For migrating 
CSCs, prediction outcomes were activation of lysine 
demethylase 5B (KDM5B) (z-score = 0.447) and inhibition 
Figure 2: Hierarchical clustering analysis. Log-transformed protein abundances of differentially regulated proteins (q-value < 0.05) 
from CSC spheroids, migrating CSCs, and differentiated cells.
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of miR-122 (z-score = –0.061). Figure 4B–4F represents 
causal associations between the predicted upstream 
regulators and their protein targets (experimental data). 
Annotations retrieved from IPA are provided in Table 1 
(differentiated dataset) and Table 2 (migrating dataset).
MicroRNAs (miRNAs) are noncoding RNA 
that suppress expression of target genes by degrading 
correspondent mRNAs or inhibiting their translation 
process [28]. Deregulation of some miRNAs has been 
reported in brain cancer including miR-124a, a miRNA 
potentially involved in GBM invasion [29]. IPA predicted 
miR-122 inhibition for migrating CSCs and miR-122 
activation for GBM differentiation (Figure 4A). Thus, 
our data suggest that miR-122 is a potential regulator of 
GBM fate. By functioning as an “ON/OFF button”, miR-
122 seems to control GBM migration and differentiation. 
IPA analysis correlated miR-122 inhibition in migrating 
CSCs with the experimentally observed upregulation 
of ARHGAP1 and LAMC1 (Figure 4B). Although, the 
relationship between ARHGAP1 and GBM migration 
is yet to be determined, LAMC1 is indeed involved 
in GBM migration [29]. IPA indicated inconsistent 
findings for ALDOA and VPS4B. Based on the Ingenuity 
Knowledge Base [22], inhibition of miR-122 correlates 
with upregulation of ALDOA and VPS4B, but we 
detected downregulation of these proteins in migrating 
CSCs (Figure 4B), which suggests involvement of other 
upstream regulators than miR-122 regulating the migrating 
CSCs proteome. As shown in Figure 4D, activation of 
miR-122 in differentiated correlated with downregulation 
of ALDOA, GNPDA1, GYS1, KHDRBS1, LAMC1, 
NPEPPS, SEPT2, SEPT9, and VPS4B indicating that these 
downregulation events are potentially related to GBM 
differentiation. Similarly, activation of Tp53 (Figure 4E) 
and inhibition of Tp63 (Figure 4F) may also have a 
potential role in GBM cell differentiation.
MiR-122 is a liver-specific miRNA [30]. However, 
this miRNA seems to be less tissue-specific in cancer as miR-
122 deregulation has been associated with colorectal cancer 
[31, 32], breast cancer [33], and gliomas [34], although 
miR-122 plays a role in hepatocellular carcinoma [35]. 
IPA predicted activation of KDM5B for migrating 
CSCs highlighting its potential role in promoting CSC 
migration. KDM5 activation was consistent with EHD1 
upregulation (Figure 4C). Interestingly, EHD1 has been 
reported as a potential inducer of cell migration and 
metastasis in non-small cell lung cancer [36]. A previous 
study showed high levels of KDM5B in glioma, inducing 
tumor growth via p21 downregulation [37]. Our data 
suggest a new role for KDM5B as a regulator of CSCs 
migration in GBM. In line with this observation, increased 
expression of KDM5B has been reported in metastatic 
breast cancer cells highlighting its potential involvement 
in cancer cell migration [38].
After shedding light on potential upstream proteome 
regulators from migrating CSC and differentiated cells, we 
used the IPA downstream effect analysis. The downstream 
effect “migration of tumor cell lines” was found 
significantly regulated in the migrating CSCs (p-value = 
0.007) and differentiated cells (p-value = 0.0003), which 
was predicted to be activated in migrating CSCs (z-score = 
0.04) and inhibited in differentiated cells (z-score = –0.158) 
Figure 3: Modulation of canonical signaling pathways in migrating CSCs and differentiated cells. Activation z-score for 
top-scoring canonical pathways from differentiated cells (left column) and migrating CSCs (right column). Positive values for activation 
z-score are in orange and denote activation. Negative values for activation z-score are in blue and indicate inhibition. Z-scores equal or very 
close to zero are in white and indicate no modulation. Not-defined z-score values are also in white.
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(Figure 5). Upregulation of CAV1, GNB2L1, RUVBL1, 
and ADAM10 as well as downregulation of PRDX2 
were consistent with activation of “migration of tumor 
cell lines” (right panel, Figure 5). Although IPA analysis 
did not predict upregulation of CTBP1 as an activator 
of migration of cancer cells, a recent report showed that 
silencing of CTBP1 suppressed migration of human 
glioma cells, indicating the potential role of CTBP1 
in GBM invasiveness [39]. Inhibition of “migration of 
tumor cell lines” was consistent with downregulation 
of FABP7, FSCN1, KHDRBS1, LGALS3, MAPK1, 
PRMT5, PTN, RUVBL2, SEPT9, and STMN1 (left panel, 
Figure 5). IPA reported “inconsistent findings with the 
state of downstream molecule” (yellow arrows) for both 
datasets indicating that IPA predicted opposing protein 
abundances. Importantly, we included “all human tissues, 
cells and cell lines” for this particular analysis. Thus, the 
term “migration of tumor cell lines” also includes other 
cancer cell lines than glial cells, which could explain 
the observed inconsistent findings as a given protein 
may favor migration of one type of cancer cell line and 
inhibition of other.
Profiling potential phenotype-specific markers
Clinicians and researchers face a great challenge 
dealing with GBM due to its heterogeneity since cancer 
cells with different phenotypes populate the tumor mass 
and surrounding areas. Since CSCs are regarded as key 
players in tumor recurrence, it is important to identify 
this phenotype. Stem cell markers such as CD133 [10], 
Musashi-1 [10], Bmi-1 [10], Sox-2 [10], Nestin [11], and 
Glut-3 [40] (to review other CSCs markers, see [6]) can be 
used to identify CSCs as well. However, we lack markers 
Table 1: Differentiated proteome: predicted upstream regulators and downstream effectors
Symbol ID Name Location Type(s)
miR-122* — microRNA 122 Cytoplasm microRNA
ALDOA P04075 aldolase, fructose-bisphosphate A Cytoplasm Enzyme
GNPDA1 P46926 glucosamine-6-phosphate deaminase 1 Cytoplasm Enzyme
GYS1 P13807 glycogen synthase 1 Cytoplasm Enzyme
KHDRBS1 Q07666 KH RNA binding domain containing, signal transduction associated 1 Nucleus transcription regulator
LAMC1 P11047 laminin subunit gamma 1 Extracellular Space Other
NPEPPS P55786 aminopeptidase puromycin sensitive Cytoplasm peptidase
SEPT2 Q15019 septin 2 Cytoplasm Enzyme
SEPT9 Q9UHD8 septin 9 Cytoplasm Enzyme
VPS4B O75351 vacuolar protein sorting 4 homolog B Cytoplasm transporter
Tp53* — tumor protein p53 Nucleus transcription regulator
CAV1 Q03135 caveolin 1 Plasma Membrane transmembrane receptor
CRYAB P02511 crystallin alpha B Nucleus Other
FKBP3 Q00688 FK506 binding protein 3 Nucleus Enzyme
PCNA P12004 proliferating cell nuclear antigen Nucleus Enzyme
STMN1 P16949 stathmin 1 Cytoplasm Other
TJP1 Q07157 tight junction protein 1 Plasma Membrane Other
XPO1 O14980 exportin 1 Nucleus transporter
Tp63* — tumor protein p63 Nucleus transcription regulator
COL4A1 P02462 collagen type IV alpha 1 chain Extracellular Space Other
FUBP1 Q96AE4 far upstream element binding protein 1 Nucleus transcription regulator
ITGB8 P26012 integrin subunit beta 8 Plasma Membrane Other
PCNA P12004 proliferating cell nuclear antigen Nucleus enzyme
TNC P24821 tenascin C Extracellular Space Other
Molecule annotation was retrieved from IPA. (*) indicates the predicted upstream regulator.
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Table 2: Migrating proteome: predicted upstream regulators and downstream effectors
Symbol ID Name Location Type(s)
miR-122* — microRNA 122 Cytoplasm microRNA
ALDOA P04075 aldolase, fructose-bisphosphate A Cytoplasm enzyme
ARHGAP1 Q07960 Rho GTPase activating protein 1 Cytoplasm other
LAMC1 P11047 laminin subunit gamma 1 Extracellular Space other
VPS4B O75351 vacuolar protein sorting 4 homolog B Cytoplasm transporter
KDM5B* — lysine demethylase 5B Nucleus transcription regulator
CAV1 Q03135 caveolin 1 Plasma Membrane transmembrane receptor
EHD1 Q9H4M9 EH domain containing 1 Cytoplasm other
FABP5 Q01469 fatty acid binding protein 5 Cytoplasm transporter
IARS2 Q9NSE4 isoleucyl-tRNA synthetase 2, mitochondrial Cytoplasm enzyme
PRPS1 P60891 phosphoribosyl pyrophosphate synthetase 1 Cytoplasm kinase
Molecule annotation was retrieved from IPA. (*) indicates the predicted upstream regulator.
Figure 4: Potential upstream regulators of migrating CSC and differentiated cancer cell proteomes. (A) Heat map with 
activation z-scores of predicted upstream regulators. (B–F) Causal connections between predicted upstream regulators and their targets from 
migrating (B–C) and differentiated (D–F) proteomes. Experimental log-transformed ratios and q-values are represented below each protein 
associated with upstream regulators. More information related to upstream regulators and their associated proteins from differentiated and 
migrating proteomes are provided in Table 1 and Table 2, respectively.
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to identify different CSCs phenotypes as, for example, 
migrating and static CSCs [9, 19].
To select potential markers for the migrating CSC 
phenotype, we focused the analysis on the top-50 proteins 
with lowest q-values from the migrating dataset. Figure 6 
represents the selected top-50 proteins including their 
cellular localization (i.e., extracellular, plasma membrane, 
and intracellular). Based on their abundance profile, proteins 
were divided into 32 upregulated and 18 downregulated, 
representing proteins more abundant in migrating CSCs or 
more abundant in CSC spheroids, respectively. To select 
potential markers for migrating CSCs, we focused our 
Figure 5: Profiling the proteins potentially involved in the migration of GBM cells. Regulated proteins potentially involved 
in the enriched downstream effect “migration of tumor cell lines” are shown.
Figure 6: Potential markers for migrating CSCs. The top-50 most confident regulated proteins (lowest q-values) from migrating 
CSCs are plotted. Numbers represent the log-transformed ratios. Numbers in the left column are from the differentiated dataset while 
numbers in the right column are from the migrating CSC dataset. Downregulation (q-value < 0.05) = green; upregulation (q-value < 0.05) = 
red; non-regulation (q-value > 0.05) = white. Cell localizations were retrieved from Ingenuity Pathway Analysis (IPA). Diff, differentiated; 
Migr, migrating CSCs; Spher, spheroid CSCs.
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analysis on the 32-upregulated proteins (Figure 6). We 
selected candidates for further validation based on antibody 
availability and novelty (not previously used as GBM 
migration marker). By using these criteria, we selected 
VCL and TF for further analysis. Although we observed 
upregulation of PLOD2 in the differentiated dataset as 
well, we selected PLOD2 for further validation because 
this enzyme has already been highlighted as a potential 
migration marker in other cancers, such as bladder cancer 
[41] and renal cell carcinoma [42]. Although PTN was 
not found differentially regulated in the migrating dataset 
(q-value = 0.485; Supplementary Table 1), we also selected 
this protein for validation because of reports indicating its 
role in glioma cell migration [43, 44].
We performed in situ immunohistochemistry using 
the same–but non-cultured–tumor tissue from which we 
obtained the spheroids to validate the selected proteins 
identified in our SuperQuant-assisted proteomic approach. 
A total of 14 areas (7 tumor core and 7 tumor periphery) 
were evaluated by manual tumor cell counting. 
Figure 7A–7D contains representative pictures of 
tissue immunostaining of TF expression in tumor core 
and periphery. We provided in the supporting information 
(Supplementary Figure 5) the immunostaining pictures of 
VCL, PTN, and PLOD2. 
In line with the SuperQuant-assisted proteomics data, 
both TF (p-value = 0.032) and PLOD2 (p-value = 0.044) 
were significantly more abundant in the tumor periphery 
than the tumor core (Figure 7E). TF is involved in the 
main iron uptake route in animals, and hence one of 
the most abundant proteins in plasma. Although TF is 
primarily synthesized in the liver, human brain (mainly 
oligodendrocytes) synthesizes TF as well [45, 46]. We found 
a strong upregulation of TF in migrating CSCs (Figure 6), 
which could be validated by immunohistochemistry 
(Figure 7D and 7E). Schonberg et al. [47] have recently 
shown that the TF gene is highly expressed in GBM CSCs 
while its expression is lower in normal neurons and glial 
progenitors. Furthermore, the authors observed a trend 
towards worse survival in patients with high levels of TF.
The elevation of PLOD2 in migrating cells is well 
in-line with other reports showing that PLOD2 is involved 
in cancer cells migration. Eisinger-Mathason et al. [48] 
showed that hypoxia in the tumor microenvironment and 
the expression of hypoxia-inducible factor-1α (HIF-1α) 
led to upregulation of PLOD2 in sarcoma. In addition, 
Chang et al. [49] observed high expression level of 
PLOD2 in invasive ductal carcinomas of breast cancer. 
PLOD2 increases collagen stability by hydroxylation of 
lysine residues in procollagen [50] leading to crosslinked 
collagen fibers that induce ECM stiffness favoring cell 
migration, invasion, and metastasis [51]. Furthermore, 
high expression levels of PLOD2 correlated with poor 
prognosis in patients with hepatocellular carcinoma [52] 
and breast carcinoma [49]. Based on mRNA sequencing 
obtained from laser-capture microdissection of whole 
tumors, Dong et al. [53] suggested PLOD2 as a prognostic 
biomarker in patients with GBM. Authors observed 
differential upregulation of PLOD2 in perinecrotic 
palisading cells–thought to be the most aggressive tumor 
cell type–compared to non-palisading cells. Moreover, a 
lower survival rate was associated with patients expressing 
higher levels of PLOD2 [53]. Our data add an additional 
level of information to this study as we detected PLOD2 
predominantly upregulated in migrating CSCs and to a 
lesser extent in differentiated cells. Data indicate both TF 
and PLOD2 as potential markers for migrating GBM cells. 
However, our results indicated that PLOD2 should not be 
used as a CSC marker since PLOD2 was also detected 
upregulated in the differentiated cells (Figure 6 and 
Supplementary Table 1).
VCL abundance was significantly lower in tumor 
periphery compared to tumor core. According to the 
immunostaining, VCL was approximately 33% less 
abundant in peripheral cells than central cells (Figure 7E). 
This stands in contrast to our proteomic data showing 
> 4-fold upregulation of VCL in migrating CSCs compared 
to CSC spheroids (Figure 6 and supporting information, 
Supplementary Table 1). Higher VCL-staining in tumor 
core may be a reflection of the recruitment of VCL-
positive microglial cells towards the tumor site [54]. 
Ubiquitously expressed, VCL is involved in cell-cell 
interaction and cell-matrix adhesion [55]. According to 
literature, there is diverging information of the role of 
VCL in cancer biology. VCL has been reported as tumor 
suppressor, illustrated by VCL downregulation in highly 
metastatic colorectal cancer [56], breast cancer [57], 
squamous carcinoma [58], and rhabdomyosarcoma [59]. 
In contrast, VCL has been found significantly upregulated 
in pancreatic cancer tissue [60] as well as in human basal 
and squamous cell tumors [58]. The diverging results 
suggest that VCL behavior in cancer cells is potentially 
tissue-specific.
Secreted PTN is a heparin-binding growth factor 
[61] and has an important role during brain development 
reaching its maximum expression level around birth 
(see [62] for review). PTN abundance was not found 
significantly regulated in the migrating CSCs dataset 
(Supplementary Table 1). Likewise, no significant change 
in PTN abundance was detected in tumor tissue although 
a trend towards increased levels was observed in the 
periphery (Figure 7E). These data stand in contrast to the 
literature reporting that PTN induces migration of some 
GBM cell lines via the receptor tyrosine phosphatase 
PTPRZ1 [43, 44]. We believe that tumor heterogeneity 
and/or the subtype of GBM used in the studies [63] may 
be responsible for such diverging results. 
CONCLUSIONS
Subjecting GBM subpopulations to a comprehensive 
quantitative proteome analysis revealed 304 differentially 
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regulated proteins. These proteins represent potential 
biomarker that may assist researchers and clinicians 
to accurately select and identify different GBM cell 
phenotypes, holding potential as next-generation brain 
cancer diagnostics and therapeutics. Our study indicated 
miR-122, KDM5B, Tp53, and Tp63 as potential regulators 
of GBM cell phenotypes. 
MATERIALS AND METHODS
Reagents
If not explicitly stated, all common solutions and 
reagents were purchased from Sigma-Aldrich and were 
of HPLC gradient grade or proteomics grade (when 
applicable).
Patient tissue and cell culture
Organotypic tumor spheroids (OTS) were obtained 
from fresh tumor tissue from a WHO grade IV GBM 
patient (referred to as T78) who underwent surgery in 2009 
as previously described [16]. Cells were cultured as free-
floating spheroids in serum-free neural stem cell medium 
[16] at 36° C in a humidified incubator with 5% CO2. We 
established this protocol to obtain CSCs in our laboratory [17] 
in accordance with the Regional Scientific Ethical Committee 
(approval number S-VF-20040102). These cells have the 
ability to form new spheroids at clonal density. They have 
a karyotype typical of GBMs, and the ability to form highly 
invasive tumors upon orthotopic xenografting. Moreover, 
they differentiate into cells expressing neuronal, astrocytic 
and oligodendrocyte markers upon culturing in serum-
containing medium. The GBM spheroids from T78 have a 
Figure 7: Validation of some potential GBM population-specific marker candidates using immunohistochemical 
staining of histological sections. Transferrin (TF) expression was monitored in tumor core (A and B) and periphery (C and D). In A and 
C, tissue was stained with haematoxylin-eosin (HE) to define tumor core and tumor periphery. In B and D, tissue was immunohistochemically 
stained using anti-TF antibody. Few tumor cells expressed transferrin in the tumor core (B) while higher abundance of TF was found in 
the tumor periphery (D). Arrows highlight cells expressing TF and these areas are magnified in the inserts. (E) Fractions of cells positive 
for vinculin (VCL), pleiotrophin (PTN), transferrin (TF) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) in tumor core 
and periphery. 
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hypermethylated O6-methylguanine-DNA methyltransferase 
(MGMT) promoter region and were derived from wildtype 
isocitrate dehydrogenase 1 (wtIDH1) tumors [16, 64].
Migration assay
Geltrex (Gibco) and serum-free medium were mixed 
(1 + 49), and 1400 µL was added to each well in 12-well 
plates. Coated plates were incubated overnight at 36° C, 
and the following morning the supernatant was aspirated. 
One spheroid (100–200 µm) was aspirated into a 0.1–2.0 µl 
pipette and placed on the coating. After incubating the 
plate for 75 minutes at 36° C, 1000 µl serum-free medium 
was added. The migration was followed with time-lapse 
microscopy for 5 days. Migration speed was calculated to 
find the optimal time to isolate the migrating cells. At the 
highest migration speed, the migrating cells were isolated 
by removing the “central” residual spheroid with a micro-
pipette. The migrating cells were then washed twice in 
phosphate buffered saline (PBS). Migrating cell pellets 
were stored at –80oC until further proteomic analysis was 
performed. For comparison with non-migrating cells, 
pellets from free-floating spheroids were obtained.
Sample preparation for quantitative proteomics
We used three independent replicates per GBM 
subpopulation in this study. Cells (about 200000 for 
each cell type) were lysed and proteins were on-filter 
digested as previously published [65]. Briefly, GBM cells 
were lysed with a solution of 2% (w/v) sodium dodecyl 
sulfate (SDS), 20 mmol/L triethylammonium bicarbonate 
(TEAB), 0.1 mol/L dithiothreitol (DTT), phosphatase 
inhibitor (PhosSTOP, Roche, Switzerland), and protease 
inhibitor (cOmplete, Roche, Switzerland). Lysis was 
enhanced and DNA filaments sheared with tip sonication 
on ice. Protein concentration was measured using Qubit 
assay (Thermo Fisher Scientific, USA) as μg/µL. Proteins 
were loaded onto spin-filter units (Vivacon 500, 30,000 
MWCO; Vivaproducts, USA) and the SDS-containing 
solution was washed out using an urea-containing solution 
(8 mol/L urea, 20 mmol/L TEAB). The lysate was loaded 
in three steps, 300 µL of urea solution was used for 
washing after each step and two washes with 600 µL of 1% 
(w/v) sodium deoxycholate (SDC), 20 mmol/L TEAB after 
all loadings. Alkylation of the reduced thiol groups was 
done with 50 mmol/L iodoacetamide, 1% (w/v) SDC, 20 
mmol/L TEAB, followed by two times wash with 250 µL 
of 1% (w/v) SDC, 20 mmol/L TEAB, proteins were 
digested overnight with trypsin (1:50) (Promega, USA) in 
1% (w/v) SDC, 20 mmol/L TEAB. Peptides were collected 
after centrifugation, and SDC was removed using ethyl 
acetate extraction from acidic solution (TFA (0.5% (v/v)).
Dimethyl labeling was performed according to a 
published protocol [66]. Briefly, 22.8 µg of peptides per 
labeling channel were dissolved in 100 µL of 0.1 mol/L 
TEAB. Peptide amount was measured by the amino acid 
analyzer (Biocrom 30, Biochrom, UK). Next, 4 µL of 4% 
(vol/vol) solution of CH2O, CD2O, or 
13CD2O was added 
and the samples were vortexed. Later, 4 µL of 0.6 mol/L 
NaBH3CN or NaBD3CN was added and the mixture was 
incubated for 60 min. at room temperature. The efficiency 
of labeling was monitored by liquid chromatography 
coupled to mass spectrometry (LC-MS) run before 
quenching the reaction. The reaction was quenched by 
adding 16 µL of 1% (vol/vol) ammonia solution and later 
8 µL of 5% (vol/vol) formic acid. After quenching labelled 
peptides were mixed in 1:1:1 ratio resulting in 3 differently 
labeled samples (Table 3). The samples were dried in a 
SpeedVac and stored at –20° C until analyzed by LC-MS.
LC-MS
Peptides were separated using Dionex Ultimate 
3000 nanoUPLC system coupled to Thermo Orbitrap 
Fusion mass spectrometer. Peptides were focused on the 
precolumn (PepMap C18 10 cm × 150 µm i.d., 5 µm) and 
eluted from analytical column (PepMap C18 50 cm × 75 
µm i.d., 3 µm) with the gradient presented in Table 4. The 
mass spectrometer was configured to run in top speed 
mode with 3 seconds cycle duration. MS1 spectra were 
recorded in Orbitrap mass analyzer from 400 to 1200 Th, 
with 120000 resolution at 200 Th, AGC target value–5e5, 
maximum accumulation time–60 ms. Ions were isolated 
using quadrupole mass filter with 2 Th wide isolation 
window and fragmented using CID in the ion trap, spectra 
were acquired in Orbitrap, with 15,000 resolution at 200 
Th, AGC target–1e4, maximum accumulation time–40 ms.
Table 3: Labeling scheme for GBM cells
Light (+ 28 Da) Medium (+32 Da) Heavy (+36 Da)
Replicate 1 Differentiated Migrating Spheroid
Replicate 2 Migrating Spheroid Differentiated
Replicate 3 Spheroid Differentiated Migrating
Table 4: LC gradient used for the analysis
Time (min) 0 5 25 205 245 270 285 287 300
% B 2 2 5 21 35 99 99 2 2
A: 0.1% formic acid; B: 80% acetonitrile in 0.1% formic acid.
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Data analysis
Data analysis was performed using Thermo Proteome 
Discoverer 2.0.0.644. Mascot 2.3 was used as the database 
search engine. SwissProt database (2014.04) restricted to 
Homo sapiens (20,340 protein sequences) combined with 
common contaminants database (231 protein sequences) 
was used. Search parameters were: parent ion mass 
tolerance–5 ppm, fragment ion mass tolerance–0.02 Th; 
fixed modifications–carboxamidomethylated cysteine, 
variable modifications–oxidized methionine and labeled 
N-terminal and lysine. Reversed decoy database was 
searched separately. For SuperQuant analysis, all MS2 
spectra were processed using home-built deconvolution 
node to produce fragmentation spectra consisting only of 
1+ fragments. Next, deconvoluted spectra were processed 
with ComplementaryFinder node before database search. 
A detailed explanation of SuperQuant data processing is 
published [14]. Database search results were evaluated using 
Percolator 2.05 [67], with the standard feature set. All PSMs 
with q-value < 0.01 were grouped together using sequence 
and theoretical mass, and the highest Percolator SVM 
score was used as the score for the group. Qvality 2.05 [68] 
was used for the estimation of q-value on the PSM group 
level, PSM groups were filtered by q-value < 0.01. Each 
PSM group gives rise to one peptide. Proteins related to the 
filtered peptides were grouped using maximum parsimony 
principle. Quantification of peptides and proteins was 
performed using standard settings provided by Proteome 
Discoverer. The mass spectrometry proteomics data were 
deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE [69] 
partner repository with the dataset identifier PXD005245.
Peptides abundancies reported by Proteome 
Discoverer were log2 transformed, normalized by 
subtracting the mean, and protein rollup was performed 
using RRollup method from DanteR package [70]. Log2-
transformed intensities were used for hierarchical clustering 
and CV calculation prior to normalization. Significantly 
regulated proteins were detected using limma R package as 
described earlier [71, 72] .
The software Ingenuity Pathway Analysis (IPA, 
Qiagen) was used to retrieve biologic and canonical 
functions. We used default settings except for the following 
instances: species = human; tissue & cell lines = astrocytes, 
microglia, neurons (all), stem cells (all), nervous system 
(all), CNS cell lines (all), neuroblastoma cell lines (all), 
tissues, primary cells and cells not otherwise specified; 
experimental p-value cutoff = 0.05. 
Immunohistochemistry
Immunohistochemical staining was performed on 
tissue samples matching the patient from whom T78 was 
derived. Briefly, formaldehyde fixed and paraffin embedded 
tissue was cut into 3 µm serial cut sections and placed on 
glass slides. The first section was stained with haematoxylin-
eosin to define tumor core and tumor periphery. Four 
sections were dewaxed, and heat-induced epitope retrieval 
followed by quenching of endogen peroxidase was 
performed. Sections were then incubated with primary 
antibodies against vinculin (VCL) (1 + 800), procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) (1 + 200), 
pleiotrophin (PTN) (1 + 400), and transferrin (TF) (1 + 800). 
Detection and staining procedures were done using EnVision 
(Dako) and the AutostainerPlus (Dako), respectively. 
Image analysis
Stained sections were evaluated using the 
Visiopharm software (Visiopharm, Hørsholm, Denmark). 
The five stainings were aligned using the TISSUEalign 
module (Visiopharm). Sample images were then collected 
for 14 regions (7 areas of tumor core and 7 areas of 
tumor periphery) using systematic uniform random 
sampling (meander fraction based) at a sampling fraction 
that resulted in approximately 5 images per region. To 
ensure optimal alignment, sample images were reviewed, 
and the two best-aligned images for each region were 
included for further analysis. Using the newCAST module 
(Visiopharm), tumor cells were counted manually to 
estimate the number of positive and negative tumor cells 
in each staining separately. Positive cell fractions were 
calculated on the basis of the total tumor cell number.
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